Linezolid (Zyvox)

Antibiotic that inhibits bacterial protein synthesis by preventing ribosomal subunit aggregation.

An oxazolidinone agent.

Presently the only drug approved for complicated skin and skin structure infections caused by methicillin resistant Staphylococcus aureus.

Treatment for gram positive infections: including vancomycin resistant enterococci, methicillin resistant Staph aureus, macrolide resistant streptococci and penicillin resistant Streptococcus pneumoniae.

Oral administration results in 100% bioavailability.

Effective for orthopedic infections due to gram positive cocci when combined with surgical debridement and removal of infected hardware or bone.

Prolonged administration associated with hematologic changes of pancytopenia, and peripheral neuropathy.

No dose adjustments necessary for renal or liver impairment or advanced age.

Has known monoamine oxidase inhibitor properties and patients receiving linezolid should avoid consuming large amounts of food or beverages with high tyramine content.

Serotonin-like drugs, noradrenergic and dopaminergic drugs can cause dangerous interactions when combined with linezolid.

More effective than vancomycin for treatment of soft tissue infections.

A bedaquiline-preomanid-linezolid regimen is effective in drug-resistant tuberculosis.

Leave a Reply

Your email address will not be published. Required fields are marked *